Piper Sandler raises BioMarin stock price target on IP settlement

Piper Sandler lifted its BioMarin (BMRN) price target to $90 from $88 and kept an Overweight rating after BioMarin’s settlement with Ascendis Pharma over Yuviwel. BioMarin will receive royalties of 20% on net U.S. sales and 18% in select international territories (incl. EU, Brazil, South Korea), extending through May 2030, which Piper said removes the Voxzogo IP litigation overhang. Additional analyst updates ranged from higher targets (e.g., Canaccord $114, Morgan Stanley $124, Jefferies $105) to a Hold stance at $70 (Stifel), supporting a modestly positive outlook.

Analysis

The market implication is less about the royalty check itself and more about the removal of a binary IP overhang that has capped BioMarin’s multiple. For BMRN, the settlement converts a litigation discount into a modest, visible revenue stream through 2030, which should matter more to EV/EBITDA than to near-term EPS; that can support a rerating if the stock can hold above the low-$60s and management avoids conservative guidance. The cleaner read-through is that BMRN now has a better shot at being valued as a durable rare-disease cash generator rather than a single-asset legal story.

For ASND, the agreement is a tax on future Yuviwel economics, but it also buys freedom to operate and likely speeds launch execution by removing injunction risk. The second-order effect is that the long-term market may be smaller than the bull case assumed because every incremental dollar carries a royalty burden, pressuring gross-to-net and the terminal multiple if the franchise is discounted like a protected monopoly. If payer adoption is slower than expected, the market could reprice ASND not on launch headlines but on the realization that incremental share gains are being monetized by a competitor.

The key contrarian point: this is probably not enough to justify chasing BMRN aggressively after the open, because the upside from royalties may be incremental versus the litigation discount being removed. The better setup may be relative value: BMRN benefits from lower uncertainty, while ASND’s upside is more dependent on launch traction data over the next 1-3 quarters. Falsifiers are simple: if Yuviwel uptake is strong enough that royalty leakage is immaterial, ASND rerates back up; if BMRN’s next print fails to reflect a cleaner model and higher confidence in the revenue base, the multiple expansion thesis stalls.

Key Decisions for Investors

• Long BMRN / short ASND as a 1-3 month relative-value trade: own the company with de-risked cash flows and short the one whose future franchise economics are now partially encumbered. Use strength in ASND to establish, and cover if BMRN fails to hold recent support after 2-3 sessions.
• If you want outright exposure, prefer BMRN on pullbacks toward the mid-$60s with a 6-12 month horizon; the trade is for multiple compression reversal rather than royalty-driven EPS upside. Falsify if management does not raise confidence on forward cash generation at the next earnings call.
• Watch ASND launch data and payer commentary over the next quarter before adding aggressively; the market has to decide whether the royalty drag is a minor leak or a structural haircut to lifetime economics. If early prescription data shows no slowdown, do not fight the tape.
• Avoid over-interpreting the upgrade cluster as a fresh fundamental inflection; treat it as valuation catch-up until independent evidence of royalty contribution shows up in BMRN’s numbers. If BMRN gaps up >8-10% on the news and volume fades, fade part of the move.